PEG-Modified Cationic Liposome for shRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering RNAi molecules, such as shRNA targeting thymidylate synthase, face challenges in achieving efficient in vivo delivery and maintaining efficacy due to rapid degradation and immune system trapping, leading to insufficient tumor targeting and potential side effects.
Innovation Solution
Electrostatic binding of shRNA to the surface of PEG-modified cationic liposomes, specifically composed of dioleoylphosphatidylethanolamine, palmitoyloleoylglycerophosphocholine, cholesterol, and O,O′-ditetradecanoyl-N-(α-trimethylammonioacetyl)diethanolaminechloride, enhances delivery and targetability to cancer cells when used in combination with chemotherapeutic agents like 5-FU or pemetrexed sodium hydrate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi molecules are administered directly, then they can inhibit tumor growth, but they quickly disintegrate and cannot be delivered at sufficient amounts
Solution Approach 1:
The patent uses PEG-modified cationic liposomes as intermediary carriers to protect RNAi molecules from degradation. The liposome structure encapsulates the shRNA, preventing direct exposure to nucleases in the bloodstream while maintaining the RNAi activity. This mediator approach allows the unstable RNAi molecules to reach tumor cells intact.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the delivery system by using PEG-modified cationic liposomes with specific compositions (DOPE, POPC, cholesterol, and DC-6-14 in a 3:2:3:2 molar ratio). These parameter changes enhance the stability, circulation time, and tumor targeting capability of the RNAi molecules.
2Reliability
If vectors encoding shRNA are injected directly into tumors, then shRNA can be delivered, but the administration method is inconvenient and not suitable for clinical application
Solution Approach 1:
The patent employs PEG-modified cationic liposomes as intermediary delivery vehicles that enable intravenous administration. The liposome carrier protects the shRNA during systemic circulation and facilitates passive tumor accumulation through the enhanced permeability and retention (EPR) effect, eliminating the need for direct tumor injection.
Solution Approach 2:
The liposome delivery system provides multiple functions: protecting shRNA from degradation, enabling systemic circulation, facilitating tumor targeting through EPR effect, and allowing convenient intravenous administration. This multi-functional approach makes the therapy suitable for clinical application.
3Reliability
If lipoplexes are used for RNAi delivery, then RNAi molecules can be delivered to tumor cells, but they are quickly trapped by the immune system upon repetitive administration
Solution Approach 1:
The patent changes the surface properties of the liposome by incorporating PEG modifications and specific lipid compositions. This parameter change creates a stealth effect that reduces recognition by the immune system, thereby extending circulation time and enabling repetitive administrations without rapid clearance.
Solution Approach 2:
The PEG-modified liposome surface creates an inert, hydrophilic barrier that prevents interaction with immune cells and proteins in the bloodstream. This inert environment protects the delivery system from immune trapping, allowing sustained circulation and repeated dosing.
4Reliability
If conventional lipoplexes are administered repeatedly, then RNAi effects can be achieved, but serious side effects occur
Solution Approach 1:
The patent optimizes the lipid composition parameters of the cationic liposome (specific ratios of DOPE, POPC, cholesterol, and DC-6-14) to reduce cytotoxicity while maintaining RNAi efficacy. The PEG modification further reduces side effects by minimizing non-specific interactions with healthy cells and reducing inflammatory responses.
Solution Approach 2:
The patent achieves selective toxicity by designing the liposome to accumulate preferentially in tumor tissue through the EPR effect. The active RNAi molecules are concentrated at the tumor site while systemic exposure to healthy tissues is minimized, thereby reducing side effects while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for enhanced delivery and antitumor effects by improving cancer cell targetability and sensitivity to chemotherapeutic agents, resulting in significant tumor growth inhibition with reduced side effects.
Implementation Method 1
when shRNA capable of inhibiting TS expression is electrostatically bound to the surface of a PEG-modified cationic liposome
Implementation Method 2
the shRNA bound to the liposome can be readily delivered to cancer cells
Implementation Method 3
RNAi molecules that cause RNA interference (hereafter referred to as 'RNAi') have been gaining attention as useful tools for treatment of tumors
Data Source
AI summary
This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3′ end.